6-K filed Aug 10, 2026 at 16:02 ET
Alpha Tau Medical reported H1 2026 financial results showing a net loss of $68.8M ($0.76/share), widened from $18.8M ($0.25/share) in H1 2025, driven by a $42.2M non-cash remeasurement of warrant liabilities as the stock price rose above the $11.50 strike. Operating loss increased 42.9% to $27.1M on higher R&D spend ($20.9M vs $14.2M). The company ended Q2 with $104.8M in cash/short-term deposits, up from $76.9M at year-end 2025, boosted by a $20M equity investment from Tolmar at a 25% premium and $15M upfront payment under the Tolmar collaboration for U.S. prostate cancer commercialization. Key clinical catalysts include completed enrollment in the pivotal ReSTART trial (top-line data late 2026/early 2027), promising REGAIN glioblastoma interim data, and a 100% objective response rate in a head & neck combo study with pembrolizumab. The Tolmar deal provides up to $161.5M in milestones plus 60% of net sales on supply, validating the platform but also capping U.S. prostate cancer upside for Alpha Tau.